Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations. Read More ›

Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time. Read More ›

Recently released study findings on PD-1/PD-L1 immunotherapy in young and elderly patients with metastatic NSCLC found the treatment is safe and effective in both patient cohorts. Read More ›

Researchers identified an association between nutritional status, treatment protocols, and survival in patients with advanced non–small-cell lung cancer. Read More ›

A recent study identified several risk factors associated with the development of nephrotoxicity when using pemetrexed in patients with non–small-cell lung cancer. Read More ›

Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended. Read More ›

Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost. Read More ›

A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status. Read More ›

Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer. Read More ›

Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications. Read More ›

Page 6 of 24


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: